Citation Information :
Salotagi S, Kannan A, Jindal A. Eternal Hunt: Unravelling the Challenge of CRE, the Quest for Perfection Continues!. Indian J Crit Care Med 2024; 28 (5):513-514.
Vijayakumar M, Selvam V, Renuka MK, Rajagopalan RE. The comparative efficacy of ceftazidime–avibactam with or without aztreonam vs polymyxins for carbapenem-resistant Enterobacteriaceae Infections: a prospective observational cohort study. Indian J of Crit Care Med: Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine 2023;27(12):923. DOI: 10.5005/jp-journals-10071-24577.
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis 2023;ciad428. DOI: 10.1093/cid/ciad428.
Soontaros S, Leelakanok N. Association between carbapenem-resistant Enterobacteriaceae and death: A systematic review and meta-analysis. Am J Infect Control 2019;47(10):1200–1212. DOI: 10.1016/j.ajic.2019.03.020.
Larcher R, Laffont-Lozes P, Roger C, Doncesco R, Groul-Viaud C, Martin A, et al. Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study. Front Cell Infect Microbiol 2022;5(12):1048633. DOI: 10.3389/fcimb.2022.1048633.
Sun S, Chen K, Kong X, Tian W, Niu S. Genetic diversity and in vitro activity of aztreonam/avibactam and ceftazidime/avibactam against carbapenem-resistant Enterobacterales: A multi-centre study in Southwest China. Infect Drug Resist 2022;1:2243–2251. DOI: 10.2147/IDR.S357396.
Lu G, Tang H, Xia Z, Yang W, Xu H, Liu Z, et al. In vitro and in vivo antimicrobial activities of ceftazidime/avibactam alone or in combination with aztreonam against carbapenem-resistant Enterobacterales. Infect Drug Resist 2022;1:7107–7116. DOI: 0.2147/IDR.S385240.
